Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
|
Results for 'Pipeline Insight: Insulin Antidiabetics' |
|
|
| Title | Publication Date | Price | Relevance |
|---|---|---|---|
| R&D Trends: Insulin Antidiabetics - The future is analogs | May 2011 | £2,405 | 100% |
| Forecast Insight: Antidiabetics Diabetes market growth driven by epidemiological trends and rich pipeline |
Sep 2010 | £9,615 | 99% |
| BRIC Diabetes Drugs Market | Apr 2009 | £2,940 | 86% |
| Pipeline Insight: Insulins Inhalable insulins unlikely to become blockbusters |
Sep 2006 | £7,210 | 78% |
| Insulin Detemir - Key patent, SPC, and data exclusivity expiry (7 country coverage) Pipeline Selector Core |
Jun 2011 | £310 | 75% |
| Novo Nordisk A/S: PharmaVitae Profile | Nov 2010 | £3,605 | 74% |
| Insulin Detemir - Key patent, SPC, and data exclusivity expiry (44 country coverage) Pipeline Selector Extended |
Jun 2011 | £705 | 73% |
| Commercial Insight: Cardiovascular and Metabolic Market Forecast | Feb 2011 | £9,615 | 73% |
| The US Pharmaceutical Market 2009-2024 | Nov 2009 | £1,499 | 59% |
| Trends in Pharmaceutical Portfolio Management Strategies to Maintain Profitability despite Adversity |
Sep 2008 | £2,405 | 56% |
- Results 1 - 10 of 10
-
-
- 1
-
-
